SVB Leerink analyst Andrew Berens said on Monday that Mirati Therapeutics could beat Amgen to market with a KRAS-blocking colon cancer drug, Investor's Business Daily
Mirati said 22% of patients with colon cancer responded to treatment with its drug adagrasib.
The results likely surpass what the FDA would require for accelerated approval, according to Berens said.
"We believe that there is likely to be an accelerated pathway available to monotherapy adagrasib, unlike [Amgen's drug] Lumakras, which will likely allow adagrasib to get first-mover advantage in colorectal cancer," he said.
When Mirati tested adagrasib in combination with Eli Lilly's Erbitux (cetuximab) that targets the EGFR receptor, the combination led to an overall response rate of 43%.
"We think a first-mover advantage in colorectal cancer could be difficult to displace and could allow access to off-label usage in earlier lines of therapy, given that EGFR inhibitors are already commercially available," he said.
To read more NewsPoints articles, click here.